Breakthrough Bacteremia with Meropenem-resistant Pseudomonas aeruginosa in Hematologic Malignancy Patients Receiving Levofloxacin Prophylaxis

Breakthrough Bacteremia with Meropenem-resistant Pseudomonas aeruginosa in Hematologic Malignancy Patients Receiving Levofloxacin Prophylaxis

Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin.

BACKGROUND Micafungin is a newly approved antifungal agent in the echinocandin class that is active against Candida species and Aspergillus species. However, this agent has limited activity against a number of fungi, including Trichosporon species. We describe 4 patients who developed disseminated trichosporonosis during the use of micafungin. No cases of trichosporonosis had been seen in the 2...

Breakthrough viridans streptococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients receiving levofloxacin prophylaxis in a Japanese hospital

BACKGROUND Breakthrough viridans streptococcal bacteremia (VSB) in patients with hematological malignancy receiving levofloxacin prophylaxis is a major blood stream infection (BSI) occurring during febrile neutropenia. However, clinical data focused on VSB in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients are lacking. METHODS The medical records of allo-HSCT recipients w...

Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies.

We read with interest the article by Caselli et al. who described a 9-year retrospective series of Pseudomonas aeruginosa (PA) bacteremia cases from 12 Italian pediatric hematology oncology centers and reported a total of 127 patients with Pseudomonas aeruginosa bloodstream infections (BSIs), with a percentage of multidrug resistant Pseudomonas aeruginosa (MDRPA) isolates of 31.4%. The 30-day m...

Pseudomonas aeruginosa bacteremia in patients with liver cirrhosis: A